Bordetella pertussis acellular antigens

Acellular pertussis antigens are *purified proteins derived from Bordetella pertussis*, including **pertussis toxin (PT)**, **filamentous hemagglutinin (FHA)**, **pertactin (PRN)**, and **fimbriae (FIM) types 2 and 3**, which are used in acellular pertussis vaccines (DTaP/Tdap) to induce protective immunity against pertussis[6][1][2][3]. These antigens are selected for their roles in bacterial adhesion (FHA, PRN, FIM) and toxicity (PT). Each contributes differently to the host-pathogen interaction and the immune response. Their inclusion in vaccines reduces reactogenicity compared to whole-cell vaccines, but the duration of immunity is shorter, and antigenic shifts (especially loss of pertactin expression) may impact vaccine effectiveness[1][6]. Immunity is mediated primarily via the generation of specific antibodies and Th2/Th17 cellular responses, but efforts are ongoing to improve Th1 responses for better protection[4]. If you need structured records for each individual antigen (e.g., "Pertussis toxin" or "Filamentous hemagglutinin"), each one can be annotated separately with its own molecular and biological properties.

Other names

acellular pertussis antigensaP antigenspertussis vaccine antigensBordetella pertussis protective antigensFHAPTPRNFIM

Induction of neutralizing and opsonizing antibodies to prevent bacterial colonization, toxin activity, and establish immunity Disruption of bacterial-host adhesion (by antibodies to FHA, PRN, FIM) Neutralization of pertussis toxin activity